Evaluation of Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling

The goal of this clinical trial is to primarily evaluate the performance of KIO017 in filling/volumizing after injection in different areas in healthy women or men, older than 18 years and seeking an improvement of her/his face aspect with resorbable filler. The main questions it aims to answer are: If the products are safe \- Acceptable local tolerance, with acceptable clinical signs after injection. If the clinical performance is as intended compared to baseline * Evaluation of performance by assessing the improvement of the appearance of the defect to be corrected by using Global Aesthetic Improvement Scale (GAIS) * Quantification of the improvement using the appropriate scale when available or other appropriates tool (angle for chin, for instance). * Pain felt during injection and after injection * Subject satisfaction

NCT Number	NCT06872359
Lead Sponsor	Kiomed Pharma Collaborators: Eurofins Dermscan Pharmascan
Conditions	Dermal Fillers, Cheek Augmentation, Lip Augmentation, Perioral Rhytids, Mid-facial Volume Deficit Related to Aging, Lip Enhancement, Lip Augmentation and Correction of Perioral Rhytids, Volume Deficiency in the Mid-Face +8 more
Enrollment	210 participants
Start Date	2025-03-25
Primary Completion	2025-12-09 (estimated)
Study Completion	2027-09-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-06